Abstract
Two prospective, controlled, multicenter, double-masked studies—one lasting 6 months (n=594) and the other, 12 months (n=787)—examined the intraocular pressure (IOP)-lowering efficacy of travoprost in 1381 black and nonblack patients with open-angle glaucoma or ocular hypertension. Investigated regimens were travoprost 0.004% once daily, latanoprost 0.005% once daily, and timolol 0.5% twice daily. In both studies, mean IOP was significantly lower in blacks treated with travoprost. The IOP reduction was also significantly greater in blacks after adjustments for age, sex, iris color, diagnosis, and corneal thickness. Timolol lowered mean IOP to a greater extent in nonblack patients. The significantly larger IOP reduction with travoprost compared with timolol in both racial groups was more pronounced in blacks. Travoprost also was superior to latanoprost in blacks. Mean changes from baseline generally were greater for black than for nonblack patients, although the differences did not achieve statistical significance. The response rate to travoprost was higher in blacks. The most common adverse effect was hyperemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore.N Engl J Med. 1991;325:1412–1417.
Hiller R, Kahn HA. Blindness from glaucoma.Am J Ophthalmol. 1975;80:62–69.
Wilson R, Richardson TM, Hertzmark E, Grant WM. Race as a risk factor for progressive glaucomatous damage.Ann Ophthalmol. 1985;17:653–659.
Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma.Am J Ophthalmol. 1985;99:383–387.
Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study.Arch Ophthalmol. 1995;113:918–924.
Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist.J Ocul Pharmacol Ther. 2001;17:421–432.
Goldberg I, Cunha-Vaz J, Jacobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.J Glaucoma. 2001;10:414–422.
Robertson SM, Sullivan EK, Silver LH, et al. Differences between black and non-black patients with open-angle glaucoma or ocular hypertension in IOP-lowering response to travoprost.Invest Ophthalmol Vis Sci. 2001;42:S559. Abstract 3004.
Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol. 2001;132:472–484.
Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.Ophthalmology. 2002;109:998–1008.
Somova L, Mufunda J. Ethnic differences of renin-sodium profile and renal prostaglandins in the pathogenesis of systemic arterial hypertension.Cent Afr J Med. 1996;42:170–175.
LaRosa FA, Gross RL, Orengo-Nania S. Central corneal thickness of Caucasians and African Americans in glaucomatous and nonglaucomatous populations.Arch Ophthalmol. 2001;119: 23–27.
Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS).Ophthalmology. 2001;108:1779–1788.
Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol.Surv Ophthalmol. 1979;23:395–398.
Saliminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol.Acta Ophthalmol. 1985;63(suppl):15–18.
Netland PA, Schwartz B, Feke GT, Takamoto T, Konno S, Goger DG. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution.J Glaucoma. 1999;8: 164–171.
Wilensky JT, Gandhi N, Pan T. Racial influence in open angle glaucoma.Ann Ophthalmol. 1978; 10:1398–1402.
Grant WM, Burke JF. Why do some people go blind from glaucoma?Ophthalmology. 1982;89: 991–998.
Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of open-angle glaucoma. The Baltimore Eye Study.JAMA. 1991;266:369–374.
Wilson MR, Hertzmark E, Walker AM, Childs-Shaw K, Epstein DL. A case-control study of risk factors in open angle glaucoma.Arch Ophthalmol. 1987;105:1066–1071.
Schwartz AL, Love DC, Schwartz MA. Long-term follow-up of argon laser trabeculoplasty for uncontrolled open-angle glaucoma.Arch Ophthalmol. 1985;103:1482–1484.
Shingleton BJ, Distler JA, Baker BH. Filtration surgery in black patients. Early results in a West Indian population.Ophthalmic Surg. 1987;18:195–199.
Berson D, Zauberman H, Landau L. Filtering operation in Africans.Am J Ophthalmol. 1969;67: 395–398.
Freedman J, Shen E, Aherens M. Trabeculectomy in a black American glaucoma population.Br J Ophthalmol. 1976;60:573–574.
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results.Ophthalmology. 1998;105:1146–1164.
Merrit JC, Perry OD, Ellison PS, et al. Effects of pilocarpine in blacks with open angle glaucoma.Glaucoma. 1985;7:127–130.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Netland, P.A., Robertson, S.M., Sullivan, E.K. et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Therapy 20, 149–163 (2003). https://doi.org/10.1007/BF02850202
Issue Date:
DOI: https://doi.org/10.1007/BF02850202